William Blair Has Bullish Forecast for Korro Bio Q3 Earnings

Key Points

• William Blair has revised upward its Q3 2025 earnings per share estimate for Korro Bio to ($2.97) from the previous forecast of ($3.03), while the consensus for the full year stands at ($9.52) per share.
• Korro Bio reported Q2 earnings of ($2.74) per share, which missed estimates of ($2.54) by ($0.20), despite exceeding revenue expectations of $0.41 million with actual revenue of $1.46 million.
• Several analysts have given Korro Bio a "buy" or "strong buy" rating, with a consensus price target of $86.83, reflecting positive sentiment despite recent target price reductions from some investment firms.

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Equities research analysts at William Blair increased their Q3 2025 earnings per share (EPS) estimates for shares of Korro Bio in a research note issued to investors on Tuesday, August 12th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($2.97) for the quarter, up from their prior forecast of ($3.03). The consensus estimate for Korro Bio's current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio's Q4 2025 earnings at ($3.00) EPS, FY2025 earnings at ($11.21) EPS, Q1 2026 earnings at ($3.06) EPS, Q2 2026 earnings at ($3.09) EPS, Q3 2026 earnings at ($3.12) EPS, Q4 2026 earnings at ($3.14) EPS, FY2026 earnings at ($12.40) EPS, FY2027 earnings at ($13.19) EPS and FY2028 earnings at ($12.55) EPS.

Korro Bio (NASDAQ:KRRO - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($2.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.54) by ($0.20). The firm had revenue of $1.46 million during the quarter, compared to analyst estimates of $0.41 million.

Other analysts also recently issued reports about the company. Raymond James Financial reduced their target price on Korro Bio from $153.00 to $147.00 and set a "strong-buy" rating for the company in a report on Wednesday, August 13th. Chardan Capital restated a "buy" rating and set a $25.00 target price on shares of Korro Bio in a research report on Wednesday, August 13th. Cantor Fitzgerald raised shares of Korro Bio to a "strong-buy" rating in a report on Tuesday, April 29th. HC Wainwright reduced their price target on shares of Korro Bio from $100.00 to $90.00 and set a "buy" rating on the stock in a report on Wednesday, August 13th. Finally, Oppenheimer lowered their price target on shares of Korro Bio from $155.00 to $90.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $86.83.

Korro Bio Trading Up 0.5%

Shares of Korro Bio stock traded up $0.09 on Friday, hitting $19.23. The stock had a trading volume of 22,652 shares, compared to its average volume of 114,534. Korro Bio has a 52-week low of $10.29 and a 52-week high of $98.00. The stock has a market cap of $180.57 million, a price-to-earnings ratio of -1.97 and a beta of 2.51. The company's 50 day moving average price is $14.48 and its 200 day moving average price is $17.81.

Hedge Funds Weigh In On Korro Bio

A number of large investors have recently modified their holdings of the company. Deep Track Capital LP raised its holdings in shares of Korro Bio by 2.9% during the 4th quarter. Deep Track Capital LP now owns 874,614 shares of the company's stock valued at $33,297,000 after buying an additional 24,614 shares in the last quarter. Driehaus Capital Management LLC boosted its holdings in Korro Bio by 17.7% during the 1st quarter. Driehaus Capital Management LLC now owns 582,449 shares of the company's stock valued at $10,140,000 after acquiring an additional 87,544 shares during the period. Point72 Asset Management L.P. boosted its holdings in Korro Bio by 11.0% during the 4th quarter. Point72 Asset Management L.P. now owns 493,997 shares of the company's stock valued at $18,806,000 after acquiring an additional 49,147 shares during the period. Cormorant Asset Management LP purchased a new stake in Korro Bio during the 1st quarter valued at about $6,621,000. Finally, Geode Capital Management LLC boosted its holdings in Korro Bio by 10.8% during the 2nd quarter. Geode Capital Management LLC now owns 155,387 shares of the company's stock valued at $1,941,000 after acquiring an additional 15,166 shares during the period. 13.18% of the stock is owned by hedge funds and other institutional investors.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).